Fig. 11.
Effects of inhibition of the Gi/phospholipase C/PKC pathway on NPY1–36/sitagliptin-induced proliferation of SHR CFs. Bar graphs show the effects of NPY1–36 (10 nmol/l) plus sitagliptin (1 μmol/l) on the number of SHR CFs in the absence and presence of pertussis toxin (100 ng/ml; A), U73122 (10 μmol/l; B), or GF109203X (10 μmol/l; C). a-dSignificantly different (by Fisher's LSD test) from the group without inhibitor and without NPY1–36/sitagliptin (a), group without inhibitor but with NPY1–36/sitagliptin (b), group with inhibitor but without NPY1–36/sitagliptin (c), or group with inhibitor and with NPY1–36/sitagliptin (d). Sample sizes (n individual experiments) are shown.